Clinical Trials e-Newsletter

Clinical Trials e-Newsletter | July 2020

Genetics and Prostate Cancer

Most cancer occurs in people who do not have a history of cancer in their family.

Learn more about the importance of knowing your gene information, go to genetic testing

The Use of Your Genetic Information to Attack Cancers

New Treatments and Clinical Trials: The Use of Genetic Information to Attack Cancers

Keith Crawford, MD, PhD

PHEN Director Clinical Trials and Patient Education

kcrawford@prostatehealthed.org

RESPOND STUDY Reveals Important Finding for Black Men About Their Prostate Cancer Genetic Information

A recent report, comparing prostate cancer genetic information from Black men to that of white men, revealed some novel differences. These differences suggest that cancer precision medicine treatments could be equally beneficial to Black men if “applied equitably”...Read More

PHEN is a partner of the Respond Study and recommends that patients consider joining the Respond Study (LINK)

Clinical Trial Highlights

KEYLYNK 010

This clinical trial is for men who have metastatic castration resistant prostate cancer (mCRPC) who have failed to respond abiraterone acetate or enzalutamide (but not both) and to chemotherapy.

Patient Summary

TRITON3

This trial is for patients with prostate cancer where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of tumors that are BRCA1, BRCA2, or ATM genetic mutations or alterations.

Patient Summary

Find Your Trial (FYT) Tool

Find A Trial That Fits

Your Needs

Click on the link below that defines where you are on your prostate cancer journey and PHEN's "Find Your Trial (FYT) Tool" will present you with a listing of available clinical trials.

Patients with Low and Intermediate Risk Prostate Cancer

High Risk Prostate Cancer Patients

Patients Treated with Prostatectomy or Radiation

Patients with Recurrent Prostate Cancer

Patients with Castration Resistant Prostate Cancer (CRPC)

Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients

Understanding Castration Resistant Prostate Cancer

Androgen deprivation (hormone) therapy, such as Lupron, works to reduce testosterone in the body to castration levels to prevent or slow the progression of prostate cancer.

What is Castration resistant Prostate Cancer?

Prostate cancer becomes Castration Resistant when the cancer progresses despite treatment with anti-androgen therapy.

What is non-Metastatic Castration Resistant Prostate Cancer?

Castration Resistant Prostate Cancer where no metastases have been detected.

What is Metastatic Castration Resistant Prostate Cancer?

Castration Resistant Prostate Cancer that has spread and metastasized to other parts of the body such as bones and other organs.

For more Clinical Trials Information

visit: www.PHENtrials.org

Bone Health Alert

It is important to remember that prostate cancer and treatments can cause bone loss, which can lead to “FRACTURES.” For more information go to bonerisk.org

PHEN TV

PHEN Clinical Trial Rally Partners